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Summary of findings {#CD009012-sec1-0001}
===================

Summary of findings for the main comparisonEarly ART compared to delayed ART initiation in HIV‐positive people with cryptococcal meningitis**Early ART compared to delayed ART initiation in HIV‐positive people with cryptococcal meningitisPatient or population:** HIV‐positive people with cryptococcal meningitis **Setting:** global **Intervention:** early ART initiation (less than 4 weeks after initiation of cryptococcal meningitis treatment) **Comparison:** delayed ART initiation (more than 4 weeks after initiation of cryptococcal meningitis treatment)**OutcomesAnticipated absolute effects^\*^ (95% CI)Relative effect (95% CI)Number of participants (trials)Certainty of the evidence (GRADE)CommentsRisk with delayed ARTRisk with early ART**All‐cause mortality at 6 to 12 months311 per 1000442 per 1000 (317 to 613)RR 1.42 (1.02 to 1.97)294 (4 RCTs)⊕⊕⊝⊝ LOW^1,2,3^Early ART initiation may increase the risk of mortality at 6 to 12 months.Cryptococcal meningitis relapse87 per 100024 per 1000 (6 to 91)RR 0.27 (0.07 to 1.04)205 (2 RCTs)⊕⊕⊝⊝ LOW^4^Early ART initiation may reduce relapses of cryptococcal meningitis compared to delayed ART initiation.Cryptococcal IRIS87 per 1000311 per 1000 (45 to 1000)RR 3.56 (0.51 to 25.02)205 (2 RCTs)⊕⊝⊝⊝ VERY LOW^4,5,6^We are uncertain as to whether or not early ART initiation increases or reduces cryptococcal IRIS events compared to delayed ART initiation.HIV virological suppression at 6 months (viral load \< 400 copies/mL)534 per 1000497 per 1000 (384 to 651)RR 0.93 (0.72 to 1.22)205 (2 RCTs)⊕⊝⊝⊝ VERY LOW^7,8^We are uncertain as to whether or not early ART initiation increases or reduces virological suppression at 6 months compared to delayed ART initiation.\***The risk in the intervention group** (and its 95% CI) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI).\
**Abbreviations: ART:** antiretroviral therapy; **CI:** confidence interval; **IRIS:** immune reconstitution inflammatory syndrome; **RCT:** randomized controlled trial; **RR:** risk ratio**GRADE Working Group grades of evidence** **High certainty:** we are very confident that the true effect lies close to that of the estimate of the effect. **Moderate certainty:** we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. **Low certainty:** our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect. **Very low certainty:** we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect.[^2]

Background {#CD009012-sec1-0002}
==========

HIV/AIDS remains one of the world\'s most significant public health challenges, particularly in low‐ and middle‐income countries. Antiretroviral therapy (ART) has substantially improved HIV prognosis by reducing associated morbidity and mortality. However uncertainty remains as to the optimal time for ART initiation when an HIV‐positive person is co‐infected with an opportunistic infection, particularly cryptococcal meningitis.

Description of the condition {#CD009012-sec2-0001}
----------------------------

Cryptococcal meningitis is an important opportunistic AIDS‐defining infection and a major contributor to high mortality before and after ART is initiated ([@CD009012-bbs2-0012]; [@CD009012-bbs2-0040]). It is caused by the encapsulated yeast *Cryptococcus neoformans*, which is inhaled as small yeast cells. Patients may present with headache, fever, malaise, and altered mental status; they may also have signs of meningism, papilloedema, and focal neurological deficits. Raised intracranial pressure likely results from poor absorption of cerebrospinal fluid (CSF); this is usually responsible for the central nervous system manifestations. In addition to clinical history and physical examination, laboratory investigations assist accurate and timely diagnosis; recommended laboratory investigations include cryptococcal antigen (CrAg) in CSF or serum, India Ink microscopy of CSF, or culture ([@CD009012-bbs2-0012]; [@CD009012-bbs2-0040]).

The case fatality rate in people with cryptococcal meningitis, the most common presentation of HIV‐related cryptococcal disease in adults, remains unacceptably high, particularly in sub‐Saharan Africa, where it is between 35% to 65% compared with 10% to 20% in most high‐income countries ([@CD009012-bbs2-0012]; [@CD009012-bbs2-0034]; [@CD009012-bbs2-0041]). In people who are immunocompromised, untreated cryptococcal meningitis will uniformly lead to death in a few weeks ([@CD009012-bbs2-0030]). Cryptococcal meningitis is a leading cause of death in HIV‐positive people and typically affects those with low cluster of differentiation 4 (CD4) counts ([@CD009012-bbs2-0035]; [@CD009012-bbs2-0043]). Amphotericin B, flucytosine, and the azoles are the mainstay antifungal treatments for cryptococcal meningitis. Drug toxicity related to amphotericin B has been reported in up to 60% of patients ([@CD009012-bbs2-0016]; [@CD009012-bbs2-0029]). Cryptococcal meningitis is less frequently described in children, although cases do occur ([@CD009012-bbs2-0033]; [@CD009012-bbs2-0038]). The best time to initiate ART in those recently diagnosed with cryptococcal meningitis remains an area of debate.

Description of the intervention {#CD009012-sec2-0002}
-------------------------------

The treatment of cryptococcal meningitis is usually initiated with a combination of antifungal agents (induction phase) followed by a single oral antifungal (consolidation phase) ([@CD009012-bbs2-0032]; [@CD009012-bbs2-0033]; [@CD009012-bbs2-0042]). The preferred induction regimen is amphotericin B combined with flucytosine, followed by oral fluconazole for the consolidation phase, and until immune reconstitution on ART. Current guidelines recommend initiating ART within four to six weeks after cryptococcal meningitis treatment has commenced ([@CD009012-bbs2-0042]).

How the intervention might work {#CD009012-sec2-0003}
-------------------------------

There remains uncertainty as to when ART should be initiated in people with cryptococcal meningitis. This is related to reports of higher mortality rates among patients who initiate ART early in cryptococcal meningitis treatment ([@CD009012-bbs2-0045]). Immune reconstitution inflammatory syndrome (IRIS), an exaggerated inflammatory response that can cause a paradoxical clinical deterioration soon after ART initiation, has frequently been described in association with cryptococcal meningitis. Some reports suggest that IRIS may contribute to higher mortality among HIV‐positive people who initiate ART early after a cryptococcal meningitis diagnosis as compared to starting later, however there is no clear evidence of such an association ([@CD009012-bbs2-0014]; [@CD009012-bbs2-0031]; [@CD009012-bbs2-0037]). Additionally, in many settings where cryptococcal meningitis is prevalent, amphotericin B and flucytosine are unavailable due to resource constraints. In such settings the use of suboptimal cryptococcal meningitis treatment regimens with inadequate fungal clearance may put patients at increased risk of developing relapses and IRIS ([@CD009012-bbs2-0013]; [@CD009012-bbs2-0027]).

Immune reconstitution inflammatory syndrome related to cryptococcal disease has been defined as events occurring within 12 months of ART initiation, reintroduction, or regimen switching after previous failure manifesting clinically as worsening disease with one or more inflammatory manifestations of cryptococcosis (meningitis, lymphadenopathy, intracranial space‐occupying lesion or lesions, multifocal disease, cutaneous or soft‐tissue lesions, pneumonitis, or pulmonary nodules) ([@CD009012-bbs2-0023]).

Although many recommendations support delaying ART initiation in people with cryptococcal meningitis ([@CD009012-bbs2-0032]; [@CD009012-bbs2-0042]), delaying ART for long periods may increase the risk of death or the development of other opportunistic infections ([@CD009012-bbs2-0028]).

Why it is important to do this review {#CD009012-sec2-0004}
-------------------------------------

Studies that have evaluated the impact of timing of ART initiation in cryptococcal meningitis on mortality have, to date, had mixed results. Most cohort studies have shown no association between ART timing and mortality ([@CD009012-bbs2-0018]; [@CD009012-bbs2-0026]; [@CD009012-bbs2-0008]). However, these cohort studies were underpowered and limited by the inherent methodological issues with the cohort study design ([Table 3](#CD009012-tbl-0003){ref-type="table"}). A previous Cochrane Review suggested that there was insufficient evidence in support of either early or delayed initiation of ART ([@CD009012-bbs2-0045]).Table 1Cohort studies evaluating time to ART initiation in cryptococcal meningitis**Trial IDDesignLocationDefinitionsStudy periodDuration of follow‐upMortalityTrial conclusionsEarly**\
**(n/N)Late**\
**(n/N)Association**[@CD009012-bbs2-0008]Retrospective cohortThailandEarly \< 1 month; late ≥ 1 month2002 to 20061050 patient years9/5246/229Adjusted HR 0.833 (95% CI 0.379 to 1.831)No difference, however underpowered and risks of selection bias and unmeasured confounders[@CD009012-bbs2-0018]Retrospective cohortUSA and Latin AmericaEarly \< 2 weeks; late 2 to 8 weeks1985 to 2014Unknown7/2414/53Adjusted OR 1.09 (95% CI 0.44 to 2.67)No difference, however underpowered and risks of selection bias and unmeasured confounders[@CD009012-bbs2-0026]Retrospective cohort (conference abstract)North AmericaEarly ≤ 14 days; late 14 to 56 days since cryptococcal meningitis diagnosis1998 to 2009Unknown7/627/67Crude HR 1.29 (0.68 to 2.43) and adjusted HR 1.30 (0.66 to 2.55)No association between timing and mortality, however unmeasured confounders and selection bias an issue.\
Low power to detect a difference[^3]

Determining when ART should be initiated after a diagnosis of cryptococcal meningitis involves balancing the survival benefit conferred by ART against the risk of IRIS. Conflicting data regarding the relationship between the timing of ART for cryptococcal meningitis and the high mortality pose a therapeutic dilemma, and studies to date have had variable results. We aimed to incorporate recent randomized controlled trials and to update the findings from the earlier review by [@CD009012-bbs2-0045].

Objectives {#CD009012-sec1-0003}
==========

To compare the outcomes of early initiation ART (less than four weeks after starting antifungal treatment) versus delayed initiation of ART (four weeks or more after starting antifungal treatment) in HIV‐positive people with concurrent cryptococcal meningitis.

Methods {#CD009012-sec1-0004}
=======

Criteria for considering studies for this review {#CD009012-sec2-0005}
------------------------------------------------

### Types of studies {#CD009012-sec3-0001}

Randomized controlled trials (RCTs).

### Types of participants {#CD009012-sec3-0002}

HIV‐positive children, adolescents, and adults with cryptococcal meningitis.

### Types of interventions {#CD009012-sec3-0003}

Early initiation of ART (ART initiated within four weeks of starting antifungal treatment) versus delayed initiation of ART (ART initiated at least four weeks after starting antifungal treatment).

### Types of outcome measures {#CD009012-sec3-0004}

#### Primary outcomes {#CD009012-sec4-0001}

All‐cause mortality

#### Secondary outcomes {#CD009012-sec4-0002}

Cryptococcal meningitis relapseRecurrence of cryptococcal meningitis symptoms in previously laboratory‐confirmed episode of cryptococcal meningitis, with resolution of symptoms for one month after treatment with participants being adherent to antifungal therapy, and now presenting with CSF antigen test or culture positive for *C neoformans*.CSF fungal clearanceMortality hazard ratio (HR)Paradoxical cryptococcal IRISFulfilling the [@CD009012-bbs2-0023] case definitionHIV virological suppression at six monthsLength of hospital stayAdverse eventsClinical adverse eventsLaboratory adverse eventsOther adverse events

Search methods for identification of studies {#CD009012-sec2-0006}
--------------------------------------------

We identified all relevant trials regardless of language or publication status.

### Electronic searches {#CD009012-sec3-0005}

We searched the following databases:

#### Routine databases {#CD009012-sec4-0003}

Cochrane Central Register of Controlled Trials (CENTRAL): Issue 7 of 12, July 2017, search date 7 August 2017MEDLINE; search date 7 August 2017 ([Appendix 1](#CD009012-sec2-0015){ref-type="app"})Embase; search date 7 August 2017 ([Appendix 2](#CD009012-sec2-0016){ref-type="app"})

#### International trial registries {#CD009012-sec4-0004}

US National Institutes of Health Ongoing Trials Register ClinicalTrials.gov ([www.clinicaltrials.gov](www.clinicaltrials.gov)), searched on 7 August 2017WHO International Clinical Trials Registry Platform (ICTRP) ([apps.who.int/trialsearch](apps.who.int/trialsearch)), searched on 7 August 2017

### Searching other resources {#CD009012-sec3-0006}

#### Conference proceedings {#CD009012-sec4-0005}

International AIDS Society (IAS) conference abstracts (2015 to 2017) ([www.iasociety.org](www.iasociety.org))Conference on Retroviruses and Opportunistic Infections (CROI) (2015 to 2017) ([www.croiconference.org/](www.croiconference.org/))

#### Other sources {#CD009012-sec4-0006}

We checked the reference lists of existing reviews and all trials identified for other potentially relevant trials.

Data collection and analysis {#CD009012-sec2-0007}
----------------------------

We conducted data collection and analysis following methods recommended in the *Cochrane Handbook for Systematic Reviews of Interventions* and the Methodological Expectations for the Conduct of Cochrane Intervention Reviews (MECIR) ([@CD009012-bbs2-0024]; [@CD009012-bbs2-0025]).

### Selection of studies {#CD009012-sec3-0007}

Two review authors (MPO and IEW) independently screened the titles and abstracts of all citations identified by searches against our inclusion criteria based on types of studies, interventions, participants, and outcomes. Both review authors evaluated the full‐text articles for inclusion. Where there was uncertainty about the inclusion of a trial, we consulted a third review author (TB).

### Data extraction and management {#CD009012-sec3-0008}

We piloted and then finalized a data extraction tool. Two review authors (MPO and IEW) independently completed data extraction for the included trials and discussed discrepancies. In case of disagreement, we consulted a third review author (TB).

For dichotomous outcomes, we extracted the number of participants who experienced the event and the number of participants randomized to each treatment group. For time‐to‐event outcomes, we extracted HRs and confidence intervals (CIs).

### Assessment of risk of bias in included studies {#CD009012-sec3-0009}

Two review authors (MPO and IEW) independently assessed the risk of bias for each trial using the Cochrane 'Risk of bias' assessment tool ([@CD009012-bbs2-0024]). We contacted trial authors for missing information or clarification, but did not receive any responses to these queries. Two review authors independently applied the 'Risk of bias' criteria to each trial, resolving any differences in opinion through discussion or by consulting a third review author (MR). We assessed the risk of bias across six domains: sequence generation, allocation concealment, blinding, incomplete outcome data, selective outcome reporting, and other potential biases ([@CD009012-bbs2-0024]). For each domain, we assigned a judgement of either low, high, or unclear risk of bias.

### Measures of treatment effect {#CD009012-sec3-0010}

We presented dichotomous data using risk ratios (RR) with 95% CIs. We used intention‐to‐treat analyses for all dichotomous data. We presented time‐to‐event data using HRs with CIs.

### Unit of analysis issues {#CD009012-sec3-0011}

No cluster‐RCTs or trials with more than one intervention arm met the inclusion criteria of this review.

### Dealing with missing data {#CD009012-sec3-0012}

Where a trial publication provided insufficient data, we contacted the trial authors to request the additional data ([@CD009012-bbs2-0001]; [@CD009012-bbs2-0003]). For analyses with persistent missing data, we used available‐case analysis and examined the robustness of this approach by examining best‐ and worse‐case scenarios. [@CD009012-bbs2-0001] provided an HR with 95% CI that was not available in the published manuscript; the method the authors used to generate this HR is uncertain.

### Assessment of heterogeneity {#CD009012-sec3-0013}

We assessed the degree of heterogeneity by a visual inspection of forest plots and by examining the Chi^2^ test.

We quantified the extent of heterogeneity by calculating an estimation of the I^2^ statistic. We followed the guidance outlined in Section 9.5.2 of the *Cochrane Handbook for Systematic Reviews of Interventions* ([@CD009012-bbs2-0024]).

0% to 40%: might not be important30% to 60%: may represent moderate heterogeneity50% to 90%: may represent substantial heterogeneity75% to 100%: considerable heterogeneity

Where heterogeneity was present in pooled effect estimates, we explored possible reasons for variability by conducting subgroup analyses. Due to the limited number of trials and participants contributing to each outcome, we were restricted in the number of subgroup analyses we could conduct.

### Assessment of reporting biases {#CD009012-sec3-0014}

We assessed publication bias qualitatively based on the characteristics of the included trials. There were insufficient trials to construct a funnel plot.

### Data synthesis {#CD009012-sec3-0015}

We performed analyses using Review Manager 5 ([@CD009012-bbs2-0036]). When trials were considered clinically and methodologically comparable, we conducted meta‐analyses using a random‐effects model. We presented narrative results of outcomes only if there was insufficient data for a meta‐analysis. For time‐to‐event data, we used HRs and CIs to generate log HRs and standard errors and used the generic inverse‐variance method to analyse these data.

#### Certainty of the evidence {#CD009012-sec4-0007}

We assessed the certainty of the evidence for each outcome using the GRADE approach ([@CD009012-bbs2-0021]), which defines the certainty of the evidence for each outcome as "the extent to which one can be confident that an estimate of effect or association is close to the quantity of specific interest" ([@CD009012-bbs2-0024]). The GRADE certainty rating has four levels: high, moderate, low, or very low. We initially categorized RCTs as high‐certainty evidence, and downgraded the certainty of the evidence after assessment of five criteria: risk of bias, consistency, directness, imprecision, and publication bias ([@CD009012-bbs2-0022]). Two review authors (IEW and MPO) independently performed this assessment, resolving any disagreements by discussion.

We constructed 'Summary of findings\' tables and GRADE evidence tables to present the results of primary and secondary outcomes. We used GRADEpro GDT software to generate the 'Summary of findings\' tables ([@CD009012-bbs2-0019]).

### Subgroup analysis and investigation of heterogeneity {#CD009012-sec3-0016}

We had initially intended to conduct subgroup analyses for the primary outcome to investigate heterogeneity produced by antifungal drug treatment, geographical region, Glasgow coma score at randomization, and CSF white blood cell count. Due to limited data, we only conducted a subgroup analysis by antifungal drug treatment.

### Sensitivity analysis {#CD009012-sec3-0017}

We used sensitivity analyses to assess the robustness of results. Where data were missing, we assessed best‐ and worst‐case scenarios to determine the possible impact of missing data on the overall effect estimates. For the cryptococcal IRIS outcome, those participants who died in the early ART and delayed ART groups may not have been missing completely at random, therefore the assumption in the main analysis (available‐case analysis) may be flawed. In addition, using an intention‐to‐treat analysis would suggest that all those who died would not have developed IRIS. We therefore conducted sensitivity analyses to determine the influence of different risks for IRIS among those who died before they could have received ART or developed IRIS. To evaluate this, we applied a best‐case scenario (8% of those who died in the early ART group would have developed IRIS and 46% of those who died in the delayed ART group would have developed IRIS) and a worst‐case scenario (46% of those who died in the early ART group would have developed IRIS and 8% of those who died in the delayed ART group would have developed IRIS). This was based on the range of reported incidence (8% to 46%) of paradoxical cryptococcal IRIS ([@CD009012-bbs2-0023]).

Viral load results were only available for a subset of participants in the two trials that reported on this outcome. For our current analysis we assumed these participants to be missing completely at random, however it is possible that participants who died before they received ART or who did not have viral load measurements done despite receiving ART differed from those who had results. We applied best‐ and worst‐case scenarios to these estimates to examine our results. These estimates were based on the range of viral load suppression rates (50% to 89%) reported by Joint United Nations Programme on HIV/AIDS (UNAIDS) for Eastern and sub‐Saharan Africa ([@CD009012-bbs2-0039]).

Results {#CD009012-sec1-0005}
=======

Description of studies {#CD009012-sec2-0008}
----------------------

Four trials met the inclusion criteria for this review ([@CD009012-bbs2-0001]; [@CD009012-bbs2-0002]; [@CD009012-bbs2-0003]; [@CD009012-bbs2-0004]). See [Table 4](#CD009012-tbl-0004){ref-type="table"}, the '[Characteristics of included studies](#CD009012-sec2-0019){ref-type="sec"}\' tables, and the '[Characteristics of excluded studies](#CD009012-sec2-0020){ref-type="sec"}\' tables for trial details.Table 2Summary of included studies**Trial IDCountryRandomized**\
**(N)Male (N; %)Age (median; IQR or mean; SD)Duration of antifungal therapy prior to randomizationAntifungal regimenTime to ART initiation after randomizationART regimen^1^Dropouts (N)EarlyDelayed**[@CD009012-bbs2-0001]Botswana2814; 5035 (32 to 41)72 hrsAmphotericin B and fluconazole7 days (range 5 to 10)32 days (range 28 to 36)TDF/FTC/EFV or NVP1[@CD009012-bbs2-0002]Uganda, South Africa17793; 5335 (28 to 40) early;\
36 (30 to 40) delayed7 to 11 daysAmphotericin B and fluconazole1 to 2 weeks after diagnosis5 weeks after diagnosisAZT/3TC/ EFV (80%),\
D4T/3TC/EFV (19%),\
TDF/3TC/EFV (1%)0[@CD009012-bbs2-0003]Zimbabwe5428; 5237 (SD 8.5) early;\
38 (SD 6.9) delayed0 daysFluconazole72 hours10 weeksD4T/3TC/ NVP6[@CD009012-bbs2-0004]^2^USA, Puerto Rico, South Africa35NRNR≤ 14 daysNR48 hours6 to 12 weeksNNRTI or PI + 2 NRTIs (3TC or FTC)NR[^4]

### Results of the search {#CD009012-sec3-0018}

We searched for trials published between 1 January 1980 and 7 August 2017. The search results are presented in a PRISMA flow diagram ([Figure 1](#CD009012-fig-0001){ref-type="fig"}). The electronic searches identified 314 titles and abstracts (80 from clinical trial registries, 180 from routine databases, and 54 from conference abstracts). After de‐duplication, 273 records underwent title and abstract screening. We identified 13 records for full‐text eligibility screening. We excluded seven of these records with reasons (two further duplicates, two journal correspondence, three wrong study design). We included six records representing four trials in the qualitative and quantitative synthesis.Figure 1Study flow diagram.

### Included studies {#CD009012-sec3-0019}

We have provided a summary of the included trials in [Table 4](#CD009012-tbl-0004){ref-type="table"} and further individual trial details in the '[Characteristics of included studies](#CD009012-sec2-0019){ref-type="sec"}\' tables.

#### Participants {#CD009012-sec4-0008}

The [@CD009012-bbs2-0004] trial included participants with several different types of opportunistic infections and did not disaggregate information for those with cryptococcal meningitis, therefore limited descriptive data could be provided for this trial.

#### Setting {#CD009012-sec4-0009}

We included four trials with 294 participants from Botswana, Puerto Rico, South Africa, Uganda, the USA, and Zimbabwe. Trials were conducted between May 2003 and November 2011.

#### Demographic characteristics {#CD009012-sec4-0010}

We did not identify any studies conducted in children less than 13 years old. Most trials included only adults aged more than 18 or 21 years, except [@CD009012-bbs2-0004], which also included adolescents aged 13 years and over. Approximately 50% of participants were male in [@CD009012-bbs2-0002], [@CD009012-bbs2-0001], and [@CD009012-bbs2-0003]. The median or mean age ranged from 35 to 38 years.

#### HIV illness {#CD009012-sec4-0011}

All trials included participants who were HIV‐positive and had a diagnosis of cryptococcal meningitis or other opportunistic infection ([@CD009012-bbs2-0004]).

#### Exclusion criteria {#CD009012-sec4-0012}

Previous or current ART use was an exclusion criterion for all trials. All trials except [@CD009012-bbs2-0004] further excluded pregnancy/lactation and concurrent central nervous system infections such as bacterial meningitis.

#### Intervention and comparison {#CD009012-sec4-0013}

##### Antifungal therapy {#CD009012-sec5-0001}

Antifungal treatment regimens differed markedly between trials. Two trials used a combination of amphotericin B and fluconazole in the induction and consolidation antifungal regimen ([@CD009012-bbs2-0001]; [@CD009012-bbs2-0002]); one trial used fluconazole only ([@CD009012-bbs2-0003]); and one trial did not report on the antifungal regimen ([@CD009012-bbs2-0004]). [@CD009012-bbs2-0001] provided amphotericin B (0.7 mg/kg/day) for two weeks, followed by oral fluconazole 400 mg daily for eight weeks. [@CD009012-bbs2-0002] administered two weeks of amphotericin B (0.7 to 1.0 mg/kg/day) combined with fluconazole (800 mg/day) followed by 800 mg of fluconazole per day for at least three weeks or until a CSF culture was sterile, followed by 400 mg of fluconazole per day thereafter, for a total consolidation period of at least 12 weeks. [@CD009012-bbs2-0003] used fluconazole 800 mg daily for 10 weeks. These three trials also reported prescribing secondary prophylaxis of 200 mg of fluconazole per day after the induction and consolidation phases of antifungal treatment.

[@CD009012-bbs2-0002] reported that participants received between 7 and 11 days of antifungal therapy prior to randomization, and [@CD009012-bbs2-0004] also allowed for ≤ 14 days of antifungal treatment prior to randomization for ART initiation. [@CD009012-bbs2-0001] randomized participants within 72 hours of antifungal therapy initiation, and [@CD009012-bbs2-0003] randomized participants at the time of cryptococcal meningitis diagnosis. Only one trial described providing supportive care in the form of electrolyte replacement, fluid management, and routine therapeutic lumbar punctures ([@CD009012-bbs2-0002]).

##### Antiretroviral therapy {#CD009012-sec5-0002}

Three trials reported using a combination of two nucleoside reverse transcriptase inhibitors including tenofovir, emtricitabine, zidovudine, and stavudine, and one non‐nucleoside reverse transcriptase inhibitor, either efavirenz or nevirapine ([@CD009012-bbs2-0001]; [@CD009012-bbs2-0002]; [@CD009012-bbs2-0003]), or protease inhibitor ([@CD009012-bbs2-0004]).

###### Early ART {#CD009012-sec6-0001}

For early initiation of ART, all trials reported starting ART within two weeks of randomization ([@CD009012-bbs2-0001]; [@CD009012-bbs2-0002]; [@CD009012-bbs2-0003]), with one trial initiating ART within 5 to 10 days ([@CD009012-bbs2-0001]), another within 1 to 2 weeks ([@CD009012-bbs2-0002]), and two trials initiating ART within 72 and 48 hours, respectively ([@CD009012-bbs2-0003]; [@CD009012-bbs2-0004]).

###### Delayed ART {#CD009012-sec6-0002}

Two trials reported initiating delayed ART around the one‐month mark: [@CD009012-bbs2-0002] (five weeks) and [@CD009012-bbs2-0001] (32 days). [@CD009012-bbs2-0003] initiated delayed ART at a median of 10 weeks, and the delayed group in [@CD009012-bbs2-0004] initiated ART between 6 and 12 weeks after randomization.

#### Outcomes {#CD009012-sec4-0014}

Three trials reported on all‐cause mortality at 6 to 12 months after randomization; we obtained additional data for this outcome directly from the authors of [@CD009012-bbs2-0003]. [@CD009012-bbs2-0004] reported 12‐month mortality, while the remaining trials reported six‐month mortality.

Only [@CD009012-bbs2-0001] and [@CD009012-bbs2-0002] reported cryptococcal meningitis relapse, CSF fungal clearance, cryptococcal IRIS, and HIV virological suppression at six months. Cerebrospinal fluid fungal clearance was reported by treatment arm as the rate of fungal clearance by [@CD009012-bbs2-0001] and as the cumulative incidence of CSF culture positivity at 14 days of amphotericin B therapy by [@CD009012-bbs2-0002].

Three trials presented mortality time‐to‐event data ([@CD009012-bbs2-0001]; [@CD009012-bbs2-0002]; [@CD009012-bbs2-0003]). [@CD009012-bbs2-0003] and [@CD009012-bbs2-0002] reported unadjusted HRs, while [@CD009012-bbs2-0001] presented a Kaplan Meier survival curve from which the HR was derived (see [Dealing with missing data](#CD009012-sec3-0012){ref-type="sec"}).

No trials reported length of hospital stay as a trial outcome; [@CD009012-bbs2-0001] reported only on prolonged hospitalizations, however this was not defined.

Varying details on adverse events were present for all trials except [@CD009012-bbs2-0004]. [@CD009012-bbs2-0001] described at least one grade 3 to 5 Division of AIDS (DAIDS) adverse event, and [@CD009012-bbs2-0002] described the cumulative incidence of such events, while [@CD009012-bbs2-0003] gave limited narrative information on adverse events.

### Excluded studies {#CD009012-sec3-0020}

We excluded seven publications after full‐text assessment for the reasons described in the '[Characteristics of excluded studies](#CD009012-sec2-0020){ref-type="sec"}\' tables ([@CD009012-bbs2-0005]; [@CD009012-bbs2-0006]; [@CD009012-bbs2-0007]; [@CD009012-bbs2-0008]; [@CD009012-bbs2-0009]; [@CD009012-bbs2-0010]; [@CD009012-bbs2-0011]).

Risk of bias in included studies {#CD009012-sec2-0009}
--------------------------------

We evaluated the risk of bias of included trials for each of the six domains (see the '[Characteristics of included studies](#CD009012-sec2-0019){ref-type="sec"}\' tables). We did a graphical summary of the 'Risk of bias\' assessment as represented in [Figure 2](#CD009012-fig-0002){ref-type="fig"} and [Figure 3](#CD009012-fig-0003){ref-type="fig"} .Figure 2'Risk of bias\' summary: review authors\' judgements about each 'Risk of bias\' item for each included trial.Figure 3'Risk of bias\' graph: review authors\' judgements about each 'Risk of bias\' item presented as percentages across all included trials.

### Allocation {#CD009012-sec3-0021}

Three of the four included trials adequately described random sequence generation and allocation concealment and were considered free of selection bias ([@CD009012-bbs2-0002]; [@CD009012-bbs2-0003]; [@CD009012-bbs2-0004]). One trial had an unclear risk of selection bias for both random sequence generation and allocation concealment, which were inadequately described ([@CD009012-bbs2-0001]).

### Blinding {#CD009012-sec3-0022}

All four trials were open‐label trials, that is participants and personnel were not blinded to treatment allocation group; we assessed these trials as having a high risk for performance bias. Outcome assessors were generally not blinded in the included trials for most outcomes. Two trials blinded IRIS outcome assessors ([@CD009012-bbs2-0002]; [@CD009012-bbs2-0004]). We did not consider blinding an issue for mortality assessment and laboratory results, as these are objective outcomes, however adverse events and IRIS are fairly subjective. As a result, we assessed most trials as having an overall unclear risk of bias for outcome assessment.

### Incomplete outcome data {#CD009012-sec3-0023}

The proportion of participants lost to follow‐up was low (\< 15%) in all trials. There was also no evidence of differential loss to follow‐up. [@CD009012-bbs2-0004] only reported attrition for the total number of randomized participants and not specifically for those with cryptococcal meningitis; overall approximately 13% of participants were lost follow‐up in this trial. We assessed all trials as at low risk of attrition bias.

### Selective reporting {#CD009012-sec3-0024}

Two trials had published protocols that were available for assessment ([@CD009012-bbs2-0001]; [@CD009012-bbs2-0002]); these trials reported all relevant outcomes and were assessed as at low risk of reporting bias. We classified two trials as at unclear risk of bias for selective outcome reporting: [@CD009012-bbs2-0004] did not have a protocol available for assessment, and the protocol for [@CD009012-bbs2-0003] was only published after the trial was completed, and no prespecified outcomes were included in the published protocol.

### Other potential sources of bias {#CD009012-sec3-0025}

One trial was at high risk of other potential sources of bias ([@CD009012-bbs2-0003]). Some reported results were not arithmetically correct, which could have had an impact on effect estimates. In addition, the authors were not consistent with the intention‐to‐treat approach, which could have affected the time‐to‐event analysis. Concerns about the results of this trial are echoed in comments from other trial authors in the same field, as referenced in the [Characteristics of included studies](#CD009012-sec2-0019){ref-type="sec"} tables.

Effects of interventions {#CD009012-sec2-0010}
------------------------

See: [Table 1](#CD009012-tbl-0001){ref-type="table"}

### Early (\< 4 weeks) versus delayed (≥ 4 weeks) ART initiation in HIV‐positive people with cryptococcal meningitis {#CD009012-sec3-0026}

Four trials with 294 participants contributed data to this comparison. See also [Table 1](#CD009012-tbl-0001){ref-type="table"} for a summary of the overall results.

#### Primary outcomes {#CD009012-sec4-0015}

##### All‐cause mortality at six to 12 months {#CD009012-sec5-0003}

There was higher mortality at this time point for those receiving early ART compared to those for whom ART was delayed (risk ratio (RR) 1.42, 95% confidence interval (CI) 1.02 to 1.97; 294 participants, 4 trials; I^2^ = 13%; [Analysis 1.1](#CD009012-fig-00101){ref-type="fig"}; [Figure 4](#CD009012-fig-0004){ref-type="fig"}). The certainty of the evidence contributing to this outcome was low due to concerns regarding risk of bias and qualitative heterogeneity in the included trials and imprecision. We conducted a sensitivity analysis including only trials at an overall low risk of bias ([Analysis 1.2](#CD009012-fig-00102){ref-type="fig"}).Figure 4Forest plot of comparison: 1 Early versus delayed ART, outcome: 1.1 All‐cause mortality at 6 to 12 months.

#### Secondary outcomes {#CD009012-sec4-0016}

##### Cryptococcal meningitis relapse {#CD009012-sec5-0004}

There was a trend towards a reduction in cryptococcal meningitis relapse with early ART compared to delayed ART. However, this effect did not reach statistical significance, as the CI included no effect (RR 0.27, 95% CI 0.07 to 1.04; 205 participants, 2 trials; I^2^ = 0%; [Analysis 1.3](#CD009012-fig-00103){ref-type="fig"}; [Figure 5](#CD009012-fig-0005){ref-type="fig"}). The certainty of the evidence contributing to this outcome was low due to imprecision (few clinical events).Figure 5Forest plot of comparison: 1 Early versus delayed ART, outcome: 1.3 Cryptococcal meningitis relapse.

##### Cerebrospinal fluid fungal clearance {#CD009012-sec5-0005}

Due to the variability in methods of reporting CSF fungal clearance, we could not pool the results from the two trials that reported on this outcome. We have presented these results narratively in [Table 5](#CD009012-tbl-0005){ref-type="table"}. Both trials found no difference in the rate of CSF fungal clearance between the two trial arms.Table 3Cerebrospinal fluid fungal clearance results**Trial IDNumber of participants assessed for this outcomeTrial conclusionsResultsEarly ARTDelayed ART**[@CD009012-bbs2-0001]^1^28No difference between groupsRate of fungal clearance: ‐0.32 log~10~ CFUs/mL/dayRate of fungal clearance: ‐0.52 log~10~ CFUs/mL/day[@CD009012-bbs2-0002]^2^166No difference between groupsCSF culture positivity at 14 days of amphotericin B therapy: cumulative incidence of 37% (95% CI 26% to 49%)CSF culture positivity at 14 days of amphotericin B therapy: cumulative incidence of 39% (95% CI 28% to 50%)[^5]

##### Mortality hazard ratio {#CD009012-sec5-0006}

Due to considerable unexplained heterogeneity in the pooled effect estimate from the trials where hazard ratios were provided (237 participants, 3 trials; I^2^ = 84%; [Analysis 1.4](#CD009012-fig-00104){ref-type="fig"}), we did not meta‐analyse this outcome.

##### Cryptococcal IRIS {#CD009012-sec5-0007}

There was a suggestion of an increased risk of cryptococcal IRIS associated with early ART (RR 3.56, 95% CI 0.51 to 25.02; 205 participants, 2 trials; I^2^ = 54%; [Analysis 1.5](#CD009012-fig-00105){ref-type="fig"}; [Figure 6](#CD009012-fig-0006){ref-type="fig"}). However, the CI around this estimate was very wide and included no effect. The certainty of the evidence for this outcome was very low due to marked imprecision of the estimate, risk of bias, and indirectness related to the IRIS assessment. We explored the use of available‐case analysis for this outcome in a sensitivity analysis ([Analysis 1.6](#CD009012-fig-00106){ref-type="fig"}, [Figure 7](#CD009012-fig-0007){ref-type="fig"}).Figure 6Forest plot of comparison: 1 Early versus delayed ART, outcome: 1.5 Cryptococcal IRIS.Figure 7Forest plot of comparison: 1 Early versus delayed ART, outcome: 1.6 Sensitivity analysis: cryptococcal IRIS.

##### HIV virological suppression {#CD009012-sec5-0008}

There was little to no difference in virological suppression at 24 weeks with early ART compared to delayed ART (RR 0.93, 95% CI 0.72 to 1.22; 205 participants, 2 trials; I^2^ = 0%; [Analysis 1.7](#CD009012-fig-00107){ref-type="fig"}). The certainty of the evidence contributing to this outcome was very low due to high risk of bias and imprecision (few clinical events). We explored the use of available‐case analysis for this outcome in a sensitivity analysis ([Analysis 1.8](#CD009012-fig-00108){ref-type="fig"}; [Figure 8](#CD009012-fig-0008){ref-type="fig"}).Figure 8Forest plot of comparison: 1 Early versus delayed ART, outcome: 1.8 Sensitivity analysis: virological suppression at 24 weeks.

##### Length of hospital stay {#CD009012-sec5-0009}

No trials reported length of hospital stay as an outcome. [@CD009012-bbs2-0001] reported only prolonged hospitalizations as 2 (15%) and 4 (29%) in early and delayed ART arms, respectively.

##### Adverse events {#CD009012-sec5-0010}

Adverse event measures were not reported consistently between trials, therefore these data could not be meta‐analysed. [@CD009012-bbs2-0001] reported that all 14 participants in the early ART arm and 13/14 participants in the delayed ART arm experienced at least one grade 3 to 5 adverse event. [@CD009012-bbs2-0002] reported the cumulative incidence of grade 3 to 5 adverse events as 84% (95% CI 74% to 90%) in the early ART group and 84% (95% CI 75% to 91%) in the delayed ART group. [@CD009012-bbs2-0003] described one episode of desquamating skin rash related to nevirapine and that liver function tests remained normal throughout the trial. [@CD009012-bbs2-0004] did not report adverse events specifically for participants with cryptococcal meningitis.

#### Subgroup analyses {#CD009012-sec4-0017}

##### All‐cause mortality by antifungal therapy {#CD009012-sec5-0011}

We subgrouped the primary outcome of all‐cause mortality according to type of antifungal therapy used. Among trials where amphotericin B therapy was combined with fluconazole ([@CD009012-bbs2-0001]; [@CD009012-bbs2-0002]), there was substantial unexplained heterogeneity between trials (I^2^ = 66%), and effect estimates were not pooled. A further trial treated cryptococcal meningitis with fluconazole monotherapy ([@CD009012-bbs2-0003]); the results of this trial indicated that those who initiated ART early had higher mortality compared to those who initiated ART later (RR 1.57, 95% CI 1.02 to 2.42; 54 participants; [Analysis 1.9](#CD009012-fig-00109){ref-type="fig"}). [@CD009012-bbs2-0004] did not specify which antifungal therapy was used (RR 0.85, 95% CI 0.08 to 8.44; 35 participants; [Analysis 1.9](#CD009012-fig-00109){ref-type="fig"}) and showed no overall difference in mortality between the treatment arms.

#### Sensitivity analyses {#CD009012-sec4-0018}

##### All‐cause mortality {#CD009012-sec5-0012}

We explored the effect of the intervention on all‐cause mortality at six months by restricting the analysis to trials with low risk of bias for sequence generation, attrition, and other bias that could influence this outcome.

Only the Cryptococcal Optimal ART Timing (COAT) trial, [@CD009012-bbs2-0002], contributed to this analysis. The results from this trial indicated a higher risk of mortality among those who initiated ART early compared to those who delayed ART (RR 1.50, 95% CI 1.02 to 2.21; 177 participants, 1 trial; [Analysis 1.2](#CD009012-fig-00102){ref-type="fig"}).

##### Cryptococcal IRIS {#CD009012-sec5-0013}

Applying an available‐case analysis (RR 2.97, 95% CI 0.38 to 23.25; [Analysis 1.6](#CD009012-fig-00106){ref-type="fig"}: [Figure 7](#CD009012-fig-0007){ref-type="fig"}) and applying a low (8%) or high (46%) occurrence of cryptococcal IRIS to the missing cases differentially in the best‐case (RR 1.56, 95% CI 0.45 to 5.40) and worst‐case scenarios (RR 3.73, 95% CI 0.37 to 38.07) only resulted in a lower or higher precision estimate. In all instances, the estimates included no effect, and CIs remained wide and included appreciable benefit and harm. These results are in keeping with the intention‐to treat analysis suggesting that this approach was reasonable for the analysis of cryptococcal IRIS.

##### Virological suppression on ART {#CD009012-sec5-0014}

We compared the use of an available‐case analysis and best‐ and worst‐case scenarios to evaluate missing data for this outcome. This resulted in a persistent result of no difference in virological suppression at six months between groups in the available‐case analysis (RR 1.10, 95% CI 0.96 to 1.27; [Analysis 1.8](#CD009012-fig-00108){ref-type="fig"}; [Figure 8](#CD009012-fig-0008){ref-type="fig"}). For the best‐case scenario, we assumed 89% virological suppression for those missing viral loads or who did not receive ART in the early ART group and 50% for those missing in the delayed ART group. This resulted in better virological suppression in the early ART group (RR 1.26, 95% CI 1.10 to 1.45). When we applied the worst‐case scenario and assumed that those missing viral loads or who did not receive ART in the early ART group had 50% suppression and in the delayed ART group had 89% suppression, this resulted in better virological suppression in the delayed ART group (RR 0.84, 95% CI 0.72 to 0.96). This suggested that the missing data for virological outcomes could bias results for this outcome and led to a downgrading of this outcome in the GRADE assessment.

#### Certainty of the evidence {#CD009012-sec4-0019}

We used GRADE to indicate the level of confidence we have in the results. The certainty of the evidence was either low or very low for most outcomes.

##### Methodological quality {#CD009012-sec5-0015}

The overall methodological quality was unclear for most trials that contributed to the analyses, due predominantly to the lack of reporting on several \'Risk of bias\' domains. We categorized [@CD009012-bbs2-0003] as at high risk of bias for three domains, and the inclusion of this trial in the mortality analyses resulted in downgrading for risk of bias for these outcomes. Due to the lack of blinding of IRIS outcome assessors in one trial, we downgraded the evidence that contributed to the IRIS analysis. Viral load analysis was not conducted for all participants who were randomized or who received ART; we downgraded the certainty of the evidence for this outcome, as it is possible that randomization was not maintained for the subgroup that was analysed for this outcome.

##### Consistency {#CD009012-sec5-0016}

We detected qualitative and quantitative heterogeneity in the analysis of mortality, which led to downgrading the certainty of the evidence for the all‐cause mortality outcome and prevented pooling of the results of the mortality hazard ratio outcome. We explored the use of different antifungal regimens in a subgroup analysis and found substantial heterogeneity between the trials providing amphotericin B, reflecting differences between these trials that could not be explained. This inconsistency could be the result of differences in the trial setting and conduct, however it was not possible to fully account for this in subgroup analyses.

##### Indirectness {#CD009012-sec5-0017}

We downgraded the cryptococcal IRIS outcome for indirectness, as we considered IRIS assessment to be quite subjective even when case definitions are applied.

##### Imprecision {#CD009012-sec5-0018}

We downgraded all outcomes due to imprecision. There were overall few clinical events contributing to each analysis. In addition, several analyses had wide CIs including no effect and appreciable harm or benefit.

##### Publication bias and other considerations {#CD009012-sec5-0019}

It was not possible to formally assess publication bias using funnel plots. However, there was no evidence of publication bias among the included trials, which presented both results with no effect or moderate effects of early ART on mortality.

Discussion {#CD009012-sec1-0006}
==========

Summary of main results {#CD009012-sec2-0011}
-----------------------

Four trials including a total of 294 participants evaluated early ART initiation compared to delayed ART initiation ([Table 1](#CD009012-tbl-0001){ref-type="table"}). The trials were conducted between 2003 and 2011, and all included people from low‐ and middle‐income countries. Two trials used amphotericin B and fluconazole for cryptococcal meningitis induction therapy; one trial used fluconazole monotherapy; and one trial did not report the induction therapy used. All trials were conducted in adults.

### Primary outcomes {#CD009012-sec3-0027}

Overall, when we pooled results from the four included trials we found that early ART initiation may increase all‐cause mortality at six to 12 months among HIV‐positive adults with cryptococcal meningitis, with low‐certainty evidence contributing to this meta‐analysis. A sensitivity analysis restricted to trials at low risk of bias showed higher risk of mortality among those initiating ART early; this analysis included one high‐quality trial (COAT trial), which was terminated early due to the higher mortality risk in the early ART group.

### Secondary outcomes {#CD009012-sec3-0028}

There was low‐certainty evidence suggesting that early ART initiation may reduce the occurrence of cryptococcal meningitis relapse. Two RCTs evaluating the risk of developing IRIS found a tendency towards increased risk of cryptococcal IRIS in the early ART group, however the very low‐certainty evidence contributing to this outcome means that we cannot say whether early ART initiation increases or decreases cryptococcal IRIS events compared to delayed ART initiation. We are uncertain if early ART affects virological suppression at six months, as the evidence contributing to this outcome was of very low certainty. Adverse events were not reported consistently between trials, therefore could not meta‐analyse this outcome. Conclusions from the authors of trials that assessed this outcome suggest no difference in grade 3 to 5 adverse events between the two treatment arms. Similarly, data from the two trials reporting on time to fungal clearance could not be pooled, and the authors of these trials concluded that there was no difference between early and delayed ART arms for this outcome.

Overall completeness and applicability of evidence {#CD009012-sec2-0012}
--------------------------------------------------

We found only a few small trials that evaluated early versus delayed ART initiation in HIV‐positive people with cryptococcal meningitis. The trials were generally conducted in low‐ and middle‐income countries and included only adult participants. The results from this review can therefore be generalized only to these groups. The overall low certainty of the evidence limits the conclusions that can be drawn from these analyses. However, the pooled results do suggest that early ART may increase all‐cause mortality. We were restricted in the number of subgroup and sensitivity analyses that we could perform due to the limited number of included trials and participants. When we restricted analyses to trials at low risk of bias for the primary outcome, the analysis contained one trial ([@CD009012-bbs2-0002]); these results showed a higher risk of mortality among those who initiated ART early. In addition, two of the included studies with the highest numbers of participants and showing higher mortality with early ART were terminated early due to excessive mortality in the early ART group. One needs to consider whether effect estimates would be higher if these trials had larger samples.

Only two trials reported using amphotericin B‐based induction therapy, which is the standard of care for treatment of people with cryptococcal meningitis. Although fluconazole monotherapy is not routinely recommended, in many low‐ and middle‐income countries this single agent may still be used, and so findings from this trial remain relevant to these settings.

Immune reconstitution inflammatory syndrome has been implicated as the reason for higher mortality in those who initiate ART early. Unfortunately, we could draw no conclusions on the effect of early ART on IRIS occurrence based on the available data.

### Certainty of the evidence {#CD009012-sec3-0029}

Overall, the certainty of the evidence contributing to all outcomes was low or very low. This was due to generally few clinical events and wide CIs around effect estimates. In addition, the poor methodological quality of some trials that contributed to the mortality, cryptococcal meningitis IRIS, and virological suppression analyses led to further downgrading of these outcomes.

Potential biases in the review process {#CD009012-sec2-0013}
--------------------------------------

We minimized selection bias by conducting an extensive literature search using a wide range of search terms and databases. Two review authors independently screened the search outputs and evaluated eligibility. In addition, we evaluated the reference lists of included papers and previous systematic reviews.

We have detailed any changes made to the trial protocol after publication and after the review process began in the [Differences between protocol and review](#CD009012-sec1-0017){ref-type="notes"} section.

Agreements and disagreements with other studies or reviews {#CD009012-sec2-0014}
----------------------------------------------------------

A previous Cochrane Review conducted by [@CD009012-bbs2-0045] included two of the four trials included in this review ([@CD009012-bbs2-0003]; [@CD009012-bbs2-0004]). They concluded that there was insufficient evidence to determine whether early ART had an effect on mortality and suggested that there was a higher risk of IRIS among those who initiated ART early. Although our review did show some evidence of higher risk of IRIS in the early ART group, the certainty of the evidence contributing to this outcome was very low. The additional trials that contributed to this updated review, and rigorous application of the GRADE tool, resulted in low‐certainty evidence of higher mortality among those who initiated ART early.

These findings contrast with cohort studies, which suggest no difference in mortality risk when comparing early ART to delayed ART ([Table 3](#CD009012-tbl-0003){ref-type="table"}). This may reflect some level of selection bias for this outcome in cohort studies.

Authors\' conclusions {#CD009012-sec1-0007}
=====================

Despite the low certainty of the evidence, it appears that initiating antiretroviral therapy (ART) within four weeks of cryptococcal meningitis diagnosis increases the risk of mortality compared to delaying ART beyond four weeks. Clinicians and guideline developers need to seriously consider the severe nature of the potential harms of initiating ART early in HIV‐positive people with cryptococcal meningitis. Findings from this Cochrane Review contributed to the formulation of the current World Health Organization (WHO) guidelines for the diagnosis, prevention, and management of cryptococcal disease in HIV‐positive adults, adolescents, and children ([@CD009012-bbs2-0042]).With this suggestion of a higher risk of mortality in HIV‐positive people with cryptococcal meningitis who initiate ART early, it is unlikely that more randomized controlled trials will be conducted that evaluate early versus delayed ART as an intervention in people with cryptococcal meningitis. Questions regarding how to best manage patients who develop cryptococcal meningitis soon after ART initiation were not addressed in this Cochrane Review and will become more relevant as rapid ART initiation becomes widespread.
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This is an update of a previous Cochrane review ([@CD009012-bbs2-0045]). The new review author team extensively revised the protocol, which is available on the CIDG website at [cidg.cochrane.org/our‐reviews](cidg.cochrane.org/our‐reviews) under the subheading 'Related content\'.

Characteristics of included studies \[ordered by study ID\] {#CD009012-sec2-0019}
===========================================================

[@CD009012-bbs2-0001]Methods**Study design:** open‐label RCTParticipants**Inclusion criteria**: adults ≥ 21 years of age: HIV‐positive, (positive enzyme‐linked immunosorbent assay and/or a detectable (i.e. \> 400 copies/mL) plasma viral load); India ink--positive cryptococcal meningitis; ART‐naive, no past use of ART besides for prevention of mother‐to‐child transmission ≥ 6 months previously; could provide written informed consent; to initiate or had initiated amphotericin B ≤ 72 hours prior to enrolment; no antifungal use within the prior 14 days; not pregnant, as determined by a negative urine β--human chorionic gonadotropin test, or were breastfeeding; not initiated antitubercular therapy ≤ 2 weeks prior to assessment; not have bacterial meningitis; unlikely to initiate immunomodulatory therapy (e.g. cancer chemotherapy) prior to the week 4 study visit; not prisoners; available CSF for determination of baseline CFUs; and would obtain outpatient care within the logistical reach of the study team. Informed consent.\
**Exclusion criteria**: patients not meeting the inclusion criteria\
**Number randomized**: 28\
**Descriptive baseline data:**\
Age: median: 35 years (IQR 32 to 41)Sex: n = 14 (52%) maleCD4 count: median: 29 (IQR 11 to 50) cells/μLFungal burden: median: 5.7 log~10~ CFU (IQR 5.2 to 6.5)GCS: median: 15 (IQR not reported)\
**Duration of antifungal therapy prior to randomization:** 72 hrs\
**Dropouts during study period:** 1Interventions**Antifungal therapy provided:** amphotericin B 0.7 mg/kg × 14 days, followed by oral fluconazole 400 mg daily × 8 weeks, followed by oral fluconazole 200 mg daily until the CD4 count is \> 200 cells/μL for 6 months\
**Supportive care:** not described\
**CSF pressure management:** not described\
**ART regimen provided:** 18 (82%) participants initiated combination TDF/FTC/EFV, whereas the remaining 4 participants initiated combination zidovudine/lamivudine plus NVP or EFV (2 participants) or TDF/FTC and NVP (2 participants).\
**Early ART:** 12 of 13 (92%) participants initiated ART at a median of 7 days (IQR 5 to 10) after randomization.\
**Delayed ART:** 10 of 14 (71%) participants in the control arm initiated ART at a median of 32 days (IQR 28 to 36) after randomization.\
**Adherence**: not reportedOutcomes**Primary outcomes**\
All‐cause mortalityCryptococcal meningitis relapse\
**Secondary outcomes**\
Time to CSF fungal clearance: \"fungal colony forming units (CFUs) were measured using a standard protocol on the initial CSF sample submitted for diagnosis, on CSF obtained at a study‐specific lumbar puncture performed 4 weeks after randomization, and on available CSF obtained from other lumbar punctures.\"Time to death (authors provided additional unpublished data ‐ HR for mortality)IRIS: defined by 2 research team physicians unblinded using [@CD009012-bbs2-0023] definitionAdverse events: incident adverse events were graded using the Division of AIDS Table for Grading Adult Adverse and Pediatric Adverse EventsVirological suppressions\
**Timing of outcome measurement**\
Study‐specific visits, performed at entry and at days 7 and 14, week 4, and monthly thereafter, included medical history and physical examination.\
HIV load, CD4 count, and complete blood count were performed at randomization, at week 4, and then at weeks 12 and 24 after the planned date of ART initiation.\
Serum chemistries were performed as above and at days 7 and 14.\
Study‐specific lumbar puncture performed 4 weeks after randomization.Notes**Country:** Botswana\
**Setting:** hospital setting\
**Dates:** September 2009 and November 2011\
**Funding:** Doris Duke Charitable Foundation via a Doris Duke Clinical Scientist Development Award (to GPB) and by the Penn Center for AIDS Research International Core\
**Other:** early study termination due to slow recruitment and funding (planned sample size = 25 per study arm)***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskThe trial authors mention randomization, but do not describe how this was done.Allocation concealment (selection bias)Unclear riskThe trial authors do not describe the allocation concealment process.Blinding of participants and personnel (performance bias) All outcomesHigh riskOpen‐label trialBlinding of outcome assessment (detection bias) All outcomesUnclear riskOutcome assessment was not reported as blinded. Immune reconstitution inflammatory syndrome assessment was unblinded. This is unlikely to bias results for mortality and laboratory tests, however bias could be introduced for adverse events and IRIS.Incomplete outcome data (attrition bias) All outcomesLow riskOnly 1 participant dropped out after randomization.Selective reporting (reporting bias)Low riskThis trial was registered on ClinicalTrials.gov in 2009:\
[clinicaltrials.gov/ct2/archive/NCT00976040](clinicaltrials.gov/ct2/archive/NCT00976040)\
[clinicaltrials.gov/ct2/show/NCT00976040](clinicaltrials.gov/ct2/show/NCT00976040)\
2 proposed outcomes were not reported:\
Clearance of *Cryptococcus neoformans* antigen from CSF and blood (time frame: 6 months)Change in the number of peripheral blood mononuclear cells responding to *C neoformans* (time frame: 4 weeks)\
We do not see these as introducing bias, as all main relevant outcomes were reported.Other biasLow riskWe did not identify any other potential sources of bias.[@CD009012-bbs2-0002]Methods**Study design**: open‐label RCTParticipants**Inclusion criteria**: 18 years or older, diagnosed with HIV infection, no previous receipt of ART, a diagnosis of cryptococcal meningitis based on CSF culture or CSF cryptococcal antigen assay, and treatment with amphotericin‐based therapy\
**Exclusion criteria**: inability to undergo follow‐up, contraindication for or refusal to undergo lumbar punctures, multiple concurrent CNS infections, previous cryptococcosis, receipt of chemotherapy or immunosuppressive agents, pregnancy, breastfeeding, and serious coexisting conditions that precluded random assignment to earlier or deferred ART.\
**Number randomized:** 177\
**Descriptive baseline data**\
Age (median (IQR) years): early ART 32 (28 to 40); delayed ART 36 (30 to 40)Sex (% male): early ART 52%; delayed ART 53%CD4 count (median (IQR) cells/μL): early ART 19 (9 to 69); delayed ART 28 (11 to 76)Fungal burden (median (IQR) log~10~ CFU/mL): early ART 5.3 (4.2 to 5.7); delayed ART 4.8 (3.8 to 5.5)GCS (% with GCS \< 15): early ART 24% ; delayed ART 30%\
**Dropouts during study period:** 1Interventions**Duration of antifungal therapy prior to randomization:** 7 to 11 days\
**Antifungal therapy provided:** induction therapy: 2 weeks amphotericin B (0.7 to 1.0 mg/kg/day) combined with fluconazole (800 mg/day)\
Followed by 800 mg of fluconazole per day for at least 3 weeks or until a CSF culture was sterile, followed by 400 mg of fluconazole per day thereafter, for a total consolidation period of at least 12 weeks. Secondary prophylaxis with fluconazole (200 mg per day) was then continued for at least 1 year.\
**Supportive care:** intravenous fluids (≥ 2 L per day) and electrolyte management\
**CSF pressure management:** additional LPs were conducted on days 7 and 14, and for control of intracranial pressure\
**ART regimen provided:** AZT, 3TC, EFV (80%), D4t, 3TC, EFV (19%), TDF, 3TC, EFV (1%)\
**Early ART initiation:** 86 (98%) received ART within 48 hrs. Median of 9 days (IQR 8 to 9) after cryptococcal meningitis diagnosis\
**Delayed ART initiation:** 62 (70%) received ART within 42‐day window. Median of 36 days (IQR 34 to 38) after cryptococcal meningitis diagnosis\
**Adherence**: not reportedOutcomes**Primary outcomes**\
All‐cause mortality. Blinded panel of 3 physicians adjudicated deaths.Cryptococcal meningitis relapse: defined as increasing growth of *Cryptococcus* on quantitative cultures after 4 weeks of treatment\
**Secondary outcomes**\
Time to CSF fungal clearance: was determined using \"the early fungicidal activity method. Microbiologic clearance of cryptococcus was measured by serial quantitative cryptococcal cultures collected at screening, study entry, study day 7, any additional therapeutic LPs, and time of outpatient clinic registration (week 4)\"Time to death: unadjusted HRIRIS as defined by [@CD009012-bbs2-0023]. Blinded panel of 3 physicians adjudicated IRIS.Adverse events: defined according to DAIDS classification 2009Virological suppression: \< 400 copies/mL at 26 weeks\
**Timing of outcome measurement:** participants were followed daily while hospitalized, then every 2 weeks for 12 weeks and monthly thereafter through 46 weeks. Lumbar punctures were performed at diagnosis and on days 7 and 14 of amphotericin therapy and as needed for the control of intracranial pressure.Notes**Country:** Uganda and South Africa\
**Setting:** 3 hospitals\
**Dates:** November 2010 to April 2011 (recruitment)\
**Funding:** funded by the National Institute of Allergy and Infectious Diseases; President\'s Emergency Plan for AIDS Relief (PEPFAR) for ART, Merck Sharp & Dohme for EFV\
**Others:** among eligible participants with cryptococcal meningitis, 29 died after diagnosis but before randomization. Data safety monitoring committee stopped trial early due to excess mortality in early ART group.***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskThe trial authors used a computer‐generated, permuted‐block randomization algorithm with blocks of different sizes in a 1:1 ratio, stratified according to site and the presence or absence of altered mental status at the time that informed consent was obtained.Allocation concealment (selection bias)Low riskSequentially numbered, opaque, sealed envelopes stored in a lockbox contained the randomization assignments for enrolled participants. Envelopes were opened after written informed consent had been obtained.Blinding of participants and personnel (performance bias) All outcomesHigh riskThis was an open‐label trial.Blinding of outcome assessment (detection bias) All outcomesUnclear riskWhile clinical assessors were blinded for IRIS and mortality, assessment of adverse events was unblinded.Incomplete outcome data (attrition bias) All outcomesLow riskThere were no cases of loss to follow‐up.Selective reporting (reporting bias)Low riskThe trial authors reported all outcomes of interest and all protocol outcomes.Other biasLow riskWe did not identify any other potential sources of bias.[@CD009012-bbs2-0003]Methods**Study design**: RCTParticipants**Inclusion criteria**: eligible participants were aged 18 years and HIV‐positive. All participants had cryptococcal meningitis confirmed by positive results of India ink identification of *Cryptococcus neoformans* in the CSF or a CSF cryptococcal polysaccharide antigen (CrAg) test (CALAS; Meridian Diagnostics), or both. Participants residing in a 50‐kilometre radius of Harare. Informed consent\
**Exclusion criteria**: previous diagnosis of or treatment for cryptococcal meningitis, currently receiving ART, receiving medications that affect the metabolism of fluconazole (especially rifampicin), pregnant or lactating, or a history of hepatic or renal dysfunction\
**Number randomized:** 54\
**Descriptive baseline data**\
Age (mean (SD) years): early ART ‐36.6 (±8.5); delayed ART ‐37.5 (±6.9)Sex (% male): early ART 50%; delayed ART 54%CD4 count (median (IQR) cells/μL): early ART 27 (17 to 69); delayed ART 51.5 (25 to 69.5)Fungal burden (CSF CrAg titre \> 1:128 (n;%)): early ART 15 (65.2); delayed ART 21 (87.5)Level of consciousness at baseline: not reported\
**Dropouts during study period:** 8 (some numerical discrepancy in flow diagram, which suggests 6)Interventions**Duration of antifungal therapy prior to randomization:** 0 days ‐ randomized at time of diagnosis and treatment initiation\
**Antifungal therapy provided:** fluconazole (800 mg once per day; Diflucan (Pfizer)), after 10 weeks reduced to a prophylactic dosage of 200 mg once per day. Where treatment failure was suspected (positive culture, positive India ink or persistently elevated CrAg titres), dosage was increased once again to 800 mg daily until CSF clear.\
**Supportive care:** not described\
**CSF pressure management:** CSF hypertension reduced if clinically indicated or CSF pressure high at study visits where LPs were conducted.\
**ART regimen:** fixed‐dose combination of stavudine (30 mg twice per day) and lamivudine (150 mg twice per day), and nevirapine (200 mg twice per day, with a 200 mg once‐daily 2‐week lead‐in dose)\
**Early ART:** started within 72 hours of randomization\
**Delayed ART:** started after 10 weeks of antifungal therapy\
**Adherence:** adherence to fluconazole and ART: self reports and pill counts at each visit (not reported in outcomes)Outcomes**Primary outcomes**\
All‐cause mortality\
**Secondary outcomes**\
Time to deathAdverse events\
**Timing of outcome assessment:** observed at outpatient clinic at 2, 4, 8, and 10 weeks, then monthly. Liver function tests conducted 6 monthly up to 2 years. Cerebrospinal fluid sampled at weeks 2, 4, and 10.Notes**Country:** Zimbabwe\
**Setting:** a tertiary referral teaching hospital in Harare\
**Dates:** October 2006 through April 2008\
**Funding:** The AIDS Care Research in Africa (ACRiA) programme and the small grants funding programme from the Infectious Diseases Society of America\
**Other:**\
Study was terminated early by the data safety monitoring committee, and the optimal sample size was not achieved.Safety concerns with regard to administration of fluconazole in high dose and nevirapine and lack of regular LFT monitoring.Concerns about censoring.Participants were discharged from hospital within 1 weekNumerical inconsistencies in results***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskA computer‐generated randomization schedule was used to assign participants to the early ART and delayed ART arms of the trial.Allocation concealment (selection bias)Low riskThe randomization sequence was concealed to the trial nurse who was responsible for participant enrolment using sealed envelopes.Blinding of participants and personnel (performance bias) All outcomesHigh riskOpen‐label trialBlinding of outcome assessment (detection bias) All outcomesUnclear riskOutcome assessment was not reported as blinded. Trial did not report on IRIS. This is unlikely to bias results for mortality and laboratory tests, however bias could be introduced for adverse events.Incomplete outcome data (attrition bias) All outcomesLow riskLosses to follow‐up low and similar in both arms (3 out of 28 and 3/5 out of 26 in early ART and delayed ART arms)Selective reporting (reporting bias)Unclear riskProtocol not available for review; outcomes not listed on ClinicalTrials.gov (protocol registered after trial was completed) [clinicaltrials.gov/ct2/show/NCT00830856](clinicaltrials.gov/ct2/show/NCT00830856)Other biasHigh riskSome reported results were not arithmetically correct, which could have had an impact on effect estimates. In addition, the authors were not consistent with the intention‐to‐treat approach, which could have affected the time‐to‐event analysis. Concerns about the results of this trial are echoed in comments from other trial authors in the same field ([@CD009012-bbs2-0017]; [@CD009012-bbs2-0015]; [@CD009012-bbs2-0020]).[@CD009012-bbs2-0004]Methods**Study design**: open‐label RCTParticipants**Inclusion criteria**: eligible participants were HIV‐positive men or women 13 years of age or older, presenting with an AIDS‐defining opportunistic infection or serious bacterial infection for which effective antimicrobial therapy was available and prescribed. To reflect clinical practice, the trial allowed presumptive and confirmed diagnoses as long as appropriate treatment for the opportunistic infection/bacterial infection had been initiated (cryptococcal disease was required to be confirmed). Participants in whom tuberculosis was diagnosed after randomization remained in the trial.\
**Exclusion criteria**: people with or on treatment for tuberculosis were excluded. People were ineligible if they had received ART within 8 weeks prior to study entry, more than 31 days of any ART within 6 months prior to study entry, or more than 1 ART regimen on which they experienced treatment failure.\
**Number randomized:** 35\
**Descriptive baseline data**\
Age: not reported for cryptococcal meningitis groupSex: not reported for cryptococcal meningitis groupCD4 count: not reported for cryptococcal meningitis groupFungal burden: not reported for cryptococcal meningitis groupLevel of consciousness at baseline: not reported for cryptococcal meningitis group\
**Dropouts during study period:** not reported for cryptococcal meningitis groupInterventions**Duration of antifungal therapy prior to randomization:** \<= 14 days\
**Antifungal therapy provided:** not reported\
**Supportive care:** not reported\
**CSF pressure management:** not reported\
**ART regimen:** choice of ART was left to the judgement of the clinician to better reflect common clinical practice.\
**Early ART:** 48 hours\
**Delayed ART:** 6 to 12 weeks\
**Adherence:** monitored by self reporting at 8, 16, 32, and 48 weeksOutcomes**Primary outcome**\
All‐cause mortality\
**Timing of outcome assessment:** participants were seen at weeks 4, 8, 12, and 16 and every 8 weeks thereafter through week 48 for clinical assessments and routine laboratory monitoring. Participants in the deferred arm shifted to follow‐up at weeks 4, 8, 12, and 16 after initiation of ART and every 8 weeks thereafter until week 48.Notes**Country:** USA and South Africa\
**Setting:** 39 AIDS Clinical Trials Units in the USA (including Puerto Rico) and Johannesburg, South Africa (which was limited to enrolling 20 participants by the trial sponsor)\
**Dates:** May 2003 to August 2007\
**Funding:** AIDS Clinical Trials Group funded by the National Institute of Allergy and Infectious Diseases\
**Other:** how cryptococcal meningitis was confirmed was not specified.***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskAfter eligibility checklist was completed, randomized treatment assignment was generated by central computer using permuted blocks within strata.Allocation concealment (selection bias)Low riskNeither the size of the blocks nor treatment assignments to other sites were public, which prevented individual investigators from deducing the assignment pattern.Blinding of participants and personnel (performance bias) All outcomesHigh riskThis was an open‐label trial.Blinding of outcome assessment (detection bias) All outcomesUnclear riskAssessment of adverse events was not blinded, which may have introduced bias for this outcome.Incomplete outcome data (attrition bias) All outcomesUnclear riskNumber of participants lost to follow‐up was not reported exactly, however the trial authors state: "Eighty‐seven percent of subjects, 123 in each arm, were evaluable for the primary endpoint", suggesting that loss to follow‐up was 13% or less, which is acceptable. It is difficult to comment specifically on participants with cryptococcal meningitis, as these results were not disaggregated.Selective reporting (reporting bias)Unclear riskThe protocol was unavailable for evaluation.Other biasUnclear riskAs the trial had so little information on the participants in our treatment group of interest, it is difficult to comment on bias related to our trial population.[^6]

Characteristics of excluded studies \[ordered by study ID\] {#CD009012-sec2-0020}
===========================================================

StudyReason for exclusion[@CD009012-bbs2-0005]Journal correspondence[@CD009012-bbs2-0006]Duplicate of [@CD009012-bbs2-0005][@CD009012-bbs2-0007]Duplicate of [@CD009012-bbs2-0005][@CD009012-bbs2-0008]Wrong study design: cohort study[@CD009012-bbs2-0009]Wrong study design: participants were not randomized to early or late ART. This is a substudy of a trial that randomized participants to different cryptococcal treatment strategies.[@CD009012-bbs2-0010]Wrong study design: cohort study[@CD009012-bbs2-0011]Journal correspondence[^7]

Mbah P Okwen, Tihana Bicanic, Marty Richardson, and Ingrid Eshun‐Wilson developed the protocol. Mbah P Okwen and Ingrid Eshun‐Wilson screened and appraised studies, consulting either Tihana Bicanic or Marty Richardson in case of disagreement. Marty Richardson provided expert contributions on statistics, and Tihana Bicanic provided expert inputs on cryptococcal meningitis content. Ingrid Eshun‐Wilson and Marty Richardson conducted the analyses. Ingrid Eshun‐Wilson and Mbah P Okwen drafted the final review, which the remaining author team reviewed.

Internal sources {#CD009012-sec2-0017}
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Centre for Evidence Based Health Care, Division of Epidemiology and Biostatistics, Department of Global Health, Stellenbosch University, South Africa.Fellowship award for Patrick OkwenLiverpool School of Tropical Medicine, UK.

External sources {#CD009012-sec2-0018}
================

Department for International Development, UK.Grant: 5242
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[^1]: Editorial Group: Cochrane Infectious Diseases Group.

[^2]: ^1^Risk of bias: downgraded by a half point due to high risk of other bias in [@CD009012-bbs2-0003]. ^2^Imprecision: downgraded by 1 for wide CIs including no effect and appreciable harm. In addition, there were few clinical events (\< 200). ^3^Heterogeneity: downgraded by a half point due to qualitative heterogeneity (different drug regimens and study methods). ^4^Imprecision: downgraded by 2 for wide CIs and very few clinical events. ^5^Risk of bias: downgraded by 1 as IRIS outcome assessors in [@CD009012-bbs2-0001] were unblinded. ^6^Indirectness: downgraded 1 as despite case definition, diagnosing IRIS can be very subjective/misdiagnosed. ^7^Risk of bias: downgraded by 2 as not all those who were randomized to early or delayed ART received ART. In addition, not all those who received ART had a viral load done. It cannot be assumed that these results are missing at random. This is explored in the sensitivity analyses. ^8^Imprecision: downgraded by 1 for few clinical events (\< 200).

[^3]: Abbreviations: ART: antiretroviral therapy; CI: confidence interval; HR: hazard ratio; OR: odds ratio

[^4]: Abbreviations: IQR: interquartile range; N: number of participants; NR: not reported; SD: standard deviation; AZT: Zidovudine; D4T: Stavudine

    ^1^TDF: tenofovir; FTC: emtricitabine; EFV: efavirenz; NVP: nevirapine; 3TC: lamivudine; NNRTI: non‐nucleoside reverse transcriptase inhibitor; NRTI: nucleoside reverse transcriptase inhibitor; PI: protease inhibitor. ^2^This trial reported results for participants with a variety of opportunistic infections and did not provide descriptive data specifically for those with cryptococcal meningitis.

[^5]: Abbreviations: CFU: colony forming units; CI: confidence interval; CSF: cerebrospinal fluid

    ^1^The trial authors reported: \"The median numbers of CSF CFU measurements for the control and intervention arms, respectively, were 3 (IQR, 2--4 \[range, 1--9\]) and 4 (IQR, 2--5 \[range, 1--7\]) (P = .2, rank‐sum test). The generalized estimating equation regression coefficient for the intervention was 0.20 (95% CI, ‐.85 to 1.25), indicating that intervention subjects had a rate of CSF clearance that tended to be 0.20 log10 CSF CFU/mL/day slower than controls, although this difference was not significant.\" ^2^The trial authors reported: \"Similar rates of CSF culture positivity at 14 days (37% in the earlier‐ART group and 39% in the deferred‐ART group, P = 0.87). Among 59 participants with positive CSF cultures at 14 days, the median cryptococcal growth was 100 CFU per millilitre (interquartile range, 15 to 500), with no significant difference between treatment groups (P = 0.13); only 5 participants had more than 10,000 CFU per millilitre in CSF.\"

[^6]: Abbreviations: ART: antiretroviral therapy; CD4: cluster of differentiation 4; CFU: colony forming units; CNS: central nervous system; CrAg: cryptococcal antigen; CSF: cerebrospinal fluid; DAIDS: Division of AIDS; GCS: Glasgow coma score; HR: hazard ratio; IQR: interquartile range; IRIS: immune reconstitution inflammatory syndrome; LP: lumbar puncture; RCT: randomized controlled trial; SD: standard deviation; TDF: Tenofovir; FTC: Emtricitabine; EFV: Efavirenz; NVP: Nevirapine; AZT: Zidovudine; LFT: Liver function test

[^7]: Abbreviations: ART: antiretroviral therapy
